Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial

To assess preliminary safety and efficacy results of the anti-programmed cell death ligand-1 (anti-PD-L1) durvalumab in combination with radiotherapy (RT) in an expansion cohort of patients included in a phase 1/2 trial at our institution. Data from patients who received concurrent palliative RT wit...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2016-11, Vol.68, p.156-162
Main Authors: Levy, Antonin, Massard, Christophe, Soria, Jean-Charles, Deutsch, Eric
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!